apomorphine hydrochloride

( Last Updated : April 26, 2021)
Generic Name:
apomorphine hydrochloride
Project Status:
Therapeutic Area:
Parkinson’s disease
Sunovion Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Project Line:
Reimbursement Review
Project Number:
Call for patient/clinician input closed:


Manufacturer Requested Reimbursement Criteria1:
Indicated for the acute, intermittent treatment of OFF episodes in patients with Parkinson's disease.
Submission Type:
Fee Schedule:
Schedule A
​Indicated for the acute, intermittent treatment of “OFF” episodes in patients with Parkinson's disease.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input open May 29, 2020
Call for patient input closed July 20, 2020

- Patient input submission received from The Michael J. Fox Foundation for Parkinson's Research, Parkinson Association of Alberta, Parkinson Canada, Parkinson Quebec and Parkinson Society BC (PSBC)

Submission received June 25, 2020

Submission was previously withdrawn and has been refiled by the sponsor


Submission accepted July 10, 2020
Review initiated July 13, 2020
Draft CADTH review report(s) provided to sponsor for comment August 28, 2020
Deadline for sponsors comments September 09, 2020
CADTH responses on draft review report(s) provided to sponsor October 08, 2020
Expert committee meeting (initial) October 21, 2020
Draft recommendation issued to sponsor November 04, 2020
End of embargo period November 18, 2020

- Reconsideration requested

Expert committee meeting February 17, 2021
Final recommendation issued to sponsor and drug plans February 24, 2021
Final recommendation posted February 26, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) March 10, 2021
CADTH review report(s) posted April 22, 2021